Inmune Bio (0Y2) Stock Price & Analysis
0Y2 Stock Chart & Stats
- Day’s Range
- EUR 1.39 - EUR 1.41
- 52-Week Range
- EUR 1.21 - EUR 1.95
- Previous Close
- EUR 1.39
- Volume
- 0
- Average Volume (3M)
- 0
- Market Cap
- EUR 36.03M
- Enterprise Value
- EUR 26.55M
- Total Cash (Recent Filing)
- EUR 18.41M
- Total Debt (Recent Filing)
- EUR 1.41M
- Price to Earnings (P/E)
- ―
- Beta
- 1.28
- Next Earnings
- Nov 05, 2026 (Est.)
- EPS Estimate
- -0.13
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Commercialization Infrastructure
Submission of the pre-MAA package and a scalable Uniphar framework move Ebstrocel beyond clinical development toward potential international access. Outsourced regulatory, logistics and market-access capabilities could support expansion without requiring INMB to build country-specific infrastructure.
Clinical And Regulatory Progress
Fast Track designation and statistically significant MINDFUL imaging results strengthen XPro’s development profile and may help prioritize regulatory interaction. The biomarker signal provides a measurable basis for continued clinical investment in a second disease area beyond the lead rare-disease program.
Low Balance-Sheet Leverage
Modest debt relative to equity limits immediate interest and repayment pressure compared with a highly leveraged development company. This provides some balance-sheet flexibility while INMB advances clinical and regulatory programs, although it does not eliminate the need for operating funding.
Bears Say
Pre-Commercial Losses
INMB has not established recurring product revenue and remains dependent on development funding rather than commercial operations. Persistent losses mean future value relies on successful approvals and launch execution, leaving limited internal earnings capacity to finance the pipeline.
Persistent Cash Burn
Ongoing operating and free-cash-flow deficits require continued access to external capital while clinical, manufacturing and regulatory work proceeds. The stated runway only reaches Q2 2027, so funding needs remain a material constraint on long-term execution and financial flexibility.
Equity Dilution
The financing adds working capital but expands the share base and creates additional potential shares through long-dated warrants. Repeated reliance on equity funding can dilute existing holders and may remain necessary as the company funds operations beyond its current runway.
Inmune Bio News
0Y2 FAQ
What was Inmune Bio’s price range in the past 12 months?
What is Inmune Bio’s market cap?
When is Inmune Bio’s upcoming earnings report date?
How were Inmune Bio’s earnings last quarter?
Is Inmune Bio overvalued?
Does Inmune Bio pay dividends?
What is Inmune Bio’s EPS estimate?
How many shares outstanding does Inmune Bio have?
What happened to Inmune Bio’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Inmune Bio?
What is the TipRanks Smart Score and how is it calculated?
Inmune Bio Stock Smart Score
Company Description
Inmune Bio
INmune Bio, Inc. is a clinical-stage biotechnology company focused on developing novel immunotherapies. Its primary objective is to harness the body's innate immune system to combat various illnesses. The company is actively engaged in developing and bringing to market therapeutic candidates designed to address a spectrum of conditions such as blood cancers, solid tumors, and chronic inflammatory diseases. Its pipeline features key development programs including: INKmune: Aimed at treating women suffering from relapsed or refractory ovarian carcinoma and individuals diagnosed with high-risk myelodysplastic syndrome. INB03: An immunotherapy targeting patients with both hematologic malignancies and solid tumors. XPro1595: Under development for the treatment of Alzheimer's disease. INmune Bio holds licensing agreements with entities including Xencor, Inc., Immune Ventures, LLC, the University of Pittsburgh, and University College London. Established in 2015, INmune Bio is headquartered in Boca Raton, Florida.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- David J. Moss
- Employees
- 21
- Website
- www.inmunebio.com
- Address
- 225 NE Mizner Boulevard, Boca Raton, FL, 33432, US
Inmune Bio (0Y2) Earnings & Revenues
0Y2 Earnings Call
Earnings Call SentimentPositive
The call conveyed strong program‑level de‑risking and tangible operational progress: formal MHRA alignment, pediatric plan approval, manufacturing readiness for Ebstracel, strengthened IP and SAB, and encouraging XPro Phase 2 imaging results with FDA Fast Track designation. Financially the quarter showed a large improvement in reported loss driven by nonrecurring items and R&D rebates, and management is controlling burn. Major near‑term milestones (UK MAA submission, EMA and US filings) are well defined. Principal concerns are a limited cash runway into Q2 2027, reliance on one‑time rebates, enrollment pace for the confirmatory trial, and financing/valuation uncertainty that could lead to dilution. On balance, the operational and clinical accomplishments outweigh the financial timing risks, but successful execution of filings and financing will be critical.
View all DE:0Y2 earnings summaries0Y2 Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 7 | 1 | 11 |
| Technical Analysis | 5 | 1 | 1 |
| Moving Averages | 2 | 0 | 10 |
